AFQ056

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mild Moderate

Conditions

Mild Moderate, or Severe Renal Impairment

Trial Timeline

Jan 1, 2011 → Aug 1, 2011

NCT ID

NCT01442259

About AFQ056

AFQ056 is a phase 1 stage product being developed by Novartis for Mild Moderate. The current trial status is completed. This product is registered under clinical trial identifier NCT01442259. Target conditions include Mild Moderate, or Severe Renal Impairment.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01491932	Phase 2	Completed	Mar 1, 2012	Oct 1, 2013	Dyskinesias
NCT01482143	Phase 1	Completed	Mar 1, 2012	Oct 1, 2013	Fragile X Syndrome
NCT01433354	Phase 2/3	Terminated	Nov 1, 2011	Sep 1, 2014	Fragile X Syndrome
NCT01348087	Phase 2	Terminated	Aug 1, 2011	Sep 1, 2014	Fragile X Syndrome
NCT01456663	Phase 1	Completed	May 1, 2011	Jul 1, 2012	Hepatic Impairment
NCT01442259	Phase 1	Completed	Jan 1, 2011	Aug 1, 2011	Mild Moderate
NCT01173731	Phase 2	Completed	Oct 1, 2010	Oct 1, 2013	Parkinson Disease
NCT00414856	Phase 1	Completed	Aug 1, 2006	—	Gastroesophageal Reflux Disease

Competing Products

20 competing products in Mild Moderate

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	44
Ranirestat + Placebo	Eisai	Phase 2/3	65
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	85
Donepezil HCl	Eisai	Approved	85
Donanemab + Aducanumab	Eli Lilly	Phase 3	77
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	52
Elagolix	AbbVie	Approved	85
AZD1446 + Placebo	AstraZeneca	Phase 2	52
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	33
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	85
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	52
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	77
MK-8931	Merck	Phase 1	33
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	23
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	77
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	85
LCZ696 + Sildenafil	Novartis	Phase 2	52
QCZ484 + Placebo	Novartis	Phase 1	33
Rivastigmine Patch	Novartis	Approved	85
Canakinumab	Novartis	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved